Antibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Immunocytochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ALX-804-579-C100 - Provider product page
- Provider
- Enzo Life Sciences
- Proper citation
- Enzo Life Sciences Cat#ALX-804-579-C100, RRID:AB_2052530
- Product name
- SEL1L monoclonal antibody (MSel1)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full length protein
- Description
- Protein G affinity purified.
- Reactivity
- Human, Mouse
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- MSel1
- Vial size
- 100 μg
- Storage
- +4°C
- Handling
- Do not freeze.
Submitted references A different pathway in the endoplasmic reticulum stress-induced expression of human HRD1 and SEL1 genes.
Simian Virus 40 depends on ER protein folding and quality control factors for entry into host cells.
SEL1L a multifaceted protein playing a role in tumor progression.
SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo.
SEL1L expression decreases breast tumor cell aggressiveness in vivo and in vitro.
Production of a monoclonal antibody directed against the recombinant SEL1L protein.
Kaneko M, Yasui S, Niinuma Y, Arai K, Omura T, Okuma Y, Nomura Y
FEBS letters 2007 Nov 27;581(28):5355-60
FEBS letters 2007 Nov 27;581(28):5355-60
Simian Virus 40 depends on ER protein folding and quality control factors for entry into host cells.
Schelhaas M, Malmström J, Pelkmans L, Haugstetter J, Ellgaard L, Grünewald K, Helenius A
Cell 2007 Nov 2;131(3):516-29
Cell 2007 Nov 2;131(3):516-29
SEL1L a multifaceted protein playing a role in tumor progression.
Biunno I, Cattaneo M, Orlandi R, Canton C, Biagiotti L, Ferrero S, Barberis M, Pupa SM, Scarpa A, Ménard S
Journal of cellular physiology 2006 Jul;208(1):23-38
Journal of cellular physiology 2006 Jul;208(1):23-38
SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo.
Cattaneo M, Orlandini S, Beghelli S, Moore PS, Sorio C, Bonora A, Bassi C, Talamini G, Zamboni G, Orlandi R, Ménard S, Bernardi LR, Biunno I, Scarpa A
Oncogene 2003 Sep 25;22(41):6359-68
Oncogene 2003 Sep 25;22(41):6359-68
SEL1L expression decreases breast tumor cell aggressiveness in vivo and in vitro.
Orlandi R, Cattaneo M, Troglio F, Casalini P, Ronchini C, Ménard S, Biunno I
Cancer research 2002 Jan 15;62(2):567-74
Cancer research 2002 Jan 15;62(2):567-74
Production of a monoclonal antibody directed against the recombinant SEL1L protein.
Orlandi R, Cattaneo M, Troglio F, Campiglio M, Biunno I, Ménard S
The International journal of biological markers 2002 Apr-Jun;17(2):104-11
The International journal of biological markers 2002 Apr-Jun;17(2):104-11
No comments: Submit comment
Supportive validation
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- Western blot analysis using MAb to SEL1L (MSel1) (Prod. No. ALX-804-579).Lane 1: MAb to SEL1L (MSel1)Lane 2: Immunoprecipitation of total lysates from BT-474 cells followed by Western blot analysis using MAb to SEL1L (MSel1) (Prod. No. ALX-804-579) (see method below)Lane 3: No lysateLane 4: MW marker. Method: Cells were lysed using a buffer containing 50mM TRIS-HCl, pH 7.4, 150mM NaCl, 10% glycerol, 0.5% NP40 and protease inhibitors (10µg/ml aproteinin, 1µg/ml leupeptin, 1µg/ml PMSF) for 10 min. at 4¡C. Lysates were then centrifuged at 12'000 rpm for 10 min. at 4¡C to remove insoluble material. Protein concentration was determined by Comassie Plus Protein Assay (Pierce, Rockford, IL). Protein extracts (1.5mg/sample) were immunoprecipitated for 2 hours at 4¡C using 5µg of SEL1L and 20µl of protein-A/G Sepharose beads (Pharmacia-Amersham). Precipitates were then separated on 10% SDS-PAGE, transferred onto nitrocellulose membrane (Amersham) and probed with 10µg/ml MAb to SEL1L (MSel1). Proteins were revealed using ECL-Plus chemiluminescence (Amersham) following the manufacturer's instructions.Note: MAb to SEL1L (MSel1) can recognize isoforms of SEL1L protein with MW lower than 88kDa.
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- Pancreatic adenocarcinomas: (b) with and (c) without SEL1L expression.